Quick Answer
GeneDx Holdings Corp. reported Stockholders Equity of $308.18 million for the year ending 2025.
- GeneDx Holdings Corp. showed an increase of +25.7% in Stockholders Equity from 2024 to 2025.
- This data is from GeneDx Holdings Corp.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2018 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: -$147.75 million | Q3 2020: -$204.37 million | Q1 2021: -$521.83 million | Q2 2021: -$566.50 million | Q3 2021: $391.02 million | Q1 2022: $329.44 million | Q2 2022: $637.27 million | Q3 2022: $561.29 million | Q1 2023: $328.47 million | Q2 2023: $296.11 million | Q3 2023: $254.26 million | Q1 2024: $207.22 million | Q2 2024: $194.04 million | Q3 2024: $204.50 million | Q1 2025: $257.41 million | Q2 2025: $277.13 million | Q3 2025: $292.26 million.
- Over the full 11 years of available data (2018 to 2025), GeneDx Holdings Corp.'s Stockholders Equity has grown by 650.6%.
- Historical annual values: Fiscal year 2025: $308.18 million | Fiscal year 2024: $245.25 million | Fiscal year 2023: $228.02 million | Fiscal year 2022: $253.71 million | Fiscal year 2021: $388.10 million | Fiscal year 2021: $391.02 million | Fiscal year 2021: -$566.50 million | Fiscal year 2021: -$521.83 million | Fiscal year 2020: -$330.05 million | Fiscal year 2019: -$88.71 million | Fiscal year 2018: -$55.97 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: